



Financial Tear Sheet

Corporate Profile

Nabriva is developing its lead product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. We are developing both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP) and intend to develop lefamulin for additional indications other than pneumonia.

Lefamulin

Nabriva's lead pleuromutilin product candidate, lefamulin, is being studied in two global, registrational Phase 3 clinical trials for the treatment of moderate to severe ...

Share Performance

Last	Change (%)	Volume	Open
9.79 USD	▼ -0.02 -(0.20%)	11,250	9.91

Recent News

08/07/17

[Nabriva Therapeutics Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights](#)

08/02/17

[Nabriva Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference](#)

07/11/17

[Nabriva Therapeutics Appoints Francesco Maria Lavino as Chief Commercial Officer](#)

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form
08/21/17	8-K
08/18/17	DEF 14A
08/11/17	8-K

Management

Colin Broom	Chief Executive Officer
Robert Crotty	General Counsel
Steven Gelone	Chief Scientific Officer and Head of Business Development

08/10/17

EFFECT

Francesco Maria Lavino	Chief Commercial Officer
Elyse Seltzer	Chief Medical Officer
Gary Sender	Chief Financial Officer
David Garrett	Vice President, Corporate Controller and Head of Investor Relations
Leanne Gasink	Vice President, Clinical Research and Development
Werner Heilmayer	Vice President CMC & IP
Ernie Kelly	Vice President Quality
Thomas Lembck	Chief Information Officer
William Sargent	Vice President Commercial Strategy and Investor Relations

Data provided by Nasdaq. Minimum 15 minutes delayed.